# Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum

## TL;DR

Blue light cystoscopy is being evaluated for its role in diagnosing and managing bladder cancer, but its benefits and cost-effectiveness remain uncertain.

## Contribution

This review provides a nuanced assessment of blue light cystoscopy's role across bladder cancer stages and highlights gaps in current evidence.

## Key findings

- BLC shows high diagnostic sensitivity but lacks clear superiority over traditional cystoscopy for all bladder cancer patients.
- Recent studies suggest the benefits of BLC are more nuanced and not universally applicable.
- Further research is needed to determine BLC's cost-effectiveness and role in surveillance and recurrence prevention.

## Abstract

This review aims to synthesize recent evidence and accounts evaluating the utility of blue light cystoscopy (BLC) across the disease spectrum of bladder cancer, including its diagnostic, surveillance, and post-treatment uses, as well as its outpatient applications, economic impact, patient perspectives, and future directions.

While initial studies on BLC suggested an advantage over traditional cystoscopy in terms of diagnostic power and recurrence rates for non-muscle invasive bladder cancer, recent studies are more equivocal on its benefits and suggest that the utilization of blue-light cystoscopy is more nuanced. Evidence is lacking on a clear superiority of blue light for all bladder cancer patients. Cost, logistics, and accuracy concerns indicate certain patients may benefit from this procedure more than others.

BLC can be a valuable adjunct to white light cystoscopy in the management of bladder cancer. It provides high diagnostic sensitivity but there are questions surrounding its cost-effectiveness, positive predictive value, and its role in effective surveillance and reduction of tumor recurrence require further longitudinal and standardized investigation.